Condition

Scleroderma clinical trials and research

• 20Clinical trials
• 35NIH research projects
• 17Countries

Newest Scleroderma clinical trials

All recruiting trials (20)

• First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis

  Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.

  Recruiting at 12 sites Phase 1/2 Prolium Bioscience, Inc · Melbourne, Victoria and 12 other locations · NCT07641634

• EVM18001 for adults with refractory lupus, myasthenia gravis, and scleroderma

  This single-arm study will test an experimental CAR‑T therapy called EVM18001 to see if it is safe and helps adults whose lupus, myasthenia gravis, or scleroderma did not respond to standard treatments.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07470151

• Biopsychosocial (BETY) exercise program for children and adults with scleroderma

  This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.

  Recruiting Hacettepe University · Ankara, Altındağ · NCT07292961

• Transcriptomic analysis of skin fibroblasts in scleroderma

  This project will analyze gene activity in skin fibroblasts from people with systemic scleroderma and from surgical controls to see if fibroblasts contribute to the disease.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT07256418

• Physical performance and daily function in people with scleroderma

  This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07183072

• Chewing and swallowing performance in people with scleroderma

  This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07182981

• AlloNK® therapy combined with rituximab for treating certain autoimmune diseases

  This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.

  Recruiting at 52 sites Phase 2 Artiva Biotherapeutics, Inc. · Tuscaloosa, Alabama and 51 other locations · NCT06991114

• Evaluating HN2301 for treating difficult cases of systemic lupus erythematosus

  This study is testing if HN2301 injections can help adults with tough cases of lupus who haven't improved with regular treatments.

  Recruiting Phase 1 Shenzhen MagicRNA Biotechnology Co., Ltd · Hefei, Anhui · NCT06801119

• Study on how diet affects autoimmune diseases in rheumatology patients

  This study looks at how changing to a healthier diet, like the Mediterranean diet, might help people with autoimmune diseases feel better and manage their symptoms.

  Recruiting University of Central Florida · Orlando, Florida · NCT06339957

• Evaluating a new CAR T cell therapy for systemic sclerosis

  This study is testing a new CAR T cell therapy to see if it can help people with systemic sclerosis feel better and manage their symptoms.

  Recruiting at 10 sites Phase 2/3 Cabaletta Bio · New Haven, Connecticut and 9 other locations · NCT06328777

• Testing new treatments for lung disease caused by scleroderma

  This study is testing new treatments for lung disease caused by scleroderma to see if they can improve lung function in adults with this condition.

  Recruiting at 23 sites Phase 2 Scleroderma Research Foundation, Inc. · Birmingham, Alabama and 33 other locations · NCT06195072

• Collection of biological samples to study systemic autoimmune diseases

  This study is collecting samples from people with autoimmune diseases like lupus and scleroderma to see if they can find new ways to diagnose and treat these conditions better.

  Recruiting University Hospital, Toulouse · Toulouse · NCT05251415

• Clopidogrel to prevent systemic sclerosis development

  This study tests if taking clopidogrel can help prevent systemic sclerosis from developing in people who have early signs of the disease.

  Recruiting at 8 sites Phase 2/3 University Hospital, Bordeaux · Bayonne and 10 other locations · NCT05098704

• Using sildenafil to treat early pulmonary vascular disease in scleroderma

  This study is testing if sildenafil can help people with scleroderma and mildly high lung pressure feel better and improve their lung function.

  Recruiting Phase 2 Johns Hopkins University · New Orleans, Louisiana and 1 other locations · NCT04797286

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• Cohort of patients with systemic sclerosis

  This study is trying to gather information from patients with systemic sclerosis over five years to better understand how the disease develops and find ways to improve treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT04265144

• Examining muscle function in patients with interstitial lung disease

  This study tests how muscle function affects breathing and exercise in people with interstitial lung disease compared to healthy individuals, and looks at how supplemental oxygen might help.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT03800017

• Registry for pregnant women with autoimmune diseases

  This study is trying to learn more about how autoimmune diseases affect pregnant women and their babies to help improve their health during and after pregnancy.

  Recruiting Duke University · Durham, North Carolina · NCT03276923

• Registry for patients with rare diseases

  This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.

  Recruiting Sanford Health · Sioux Falls, South Dakota · NCT01793168

• Registry for understanding Scleroderma at the Hospital for Special Surgery

  This study is collecting health information and blood samples from people with Scleroderma to better understand the disease and improve treatment options.

  Recruiting Hospital for Special Surgery, New York · New York, New York · NCT01656447

NIH-funded research (35)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Angiogenesis imaging in scleroderma to track digital ulcers

  A patient-friendly look at using a special imaging tracer to watch blood vessel growth in the hands of people with scleroderma to help manage digital ulcers.

  NIH research Yale University · New Haven, United States · NIH-11439475

• Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma

  A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11419890

• Pediatric Scleroderma: Mapping Cells and Tissues to Personalize Care

  A study will map the different cell types and tissue patterns in skin from children with scleroderma to identify patient-specific disease subtypes that could guide targeted therapies.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11404087

• CD38 and NAD metabolism in scleroderma (systemic sclerosis) fibrosis

  This grant explores how changes in NAD metabolism related to CD38 and NNMT may drive scarring in systemic sclerosis and tests new ways to stop it.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11401084

• ISG15-positive monocytes and SPP1 macrophages in scleroderma lung disease

  This grant studies a specific immune cell pathway in systemic sclerosis with lung scarring to help predict how the disease progresses.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11392058

• Autoantibodies define scleroderma subgroups with distinct cancer links

  Researchers are studying how specific autoantibodies in scleroderma patients relate to cancer timing and risk.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11382187

• A new RNA drug to reduce heart scarring in scleroderma patients

  Aims to test a small RNA therapy that could reduce heart fibrosis and improve heart function in people with scleroderma-related heart disease.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11339407

• Lymphatic ERG signaling and fibrosis in scleroderma

  This grant explores how a key gene pathway involved in lymphatic vessels may contribute to fibrosis in scleroderma, with the goal of finding new targets to improve vascular health and tissue healing.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11336853

• Repurposing esomeprazole to treat scleroderma

  Aims to test whether esomeprazole, a heartburn drug, could help people with scleroderma by stopping or slowing skin and organ scarring.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11325741

• Measuring skin changes in scleroderma with a new imaging method

  A new, painless imaging method called SFDI would be tested to quantify skin changes in people with systemic sclerosis to see if it provides a more objective, reliable measure than current skin scoring.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11311281

• New mouse and human lung models to study how T cells drive scleroderma-related lung fibrosis

  Aims to understand how specific T cell types contribute to lung scarring in scleroderma by using advanced mouse and human lung models.

  NIH research National Jewish Health · Denver, United States · NIH-11305094

• How the Pfizer COVID-19 vaccine affects people with lupus or scleroderma

  This project looks at immune responses to the Pfizer (BNT162b2) COVID-19 vaccine in people with lupus or scleroderma to understand why some have weaker protection.

  NIH research Stanford University · Stanford, United States · NIH-11262193

• Hippo signaling and scarring in scleroderma

  This project looks at whether blocking a cell signal called the Hippo pathway can reduce the skin and organ scarring that affects people with scleroderma.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11239132

• Autoantibodies link scleroderma subtypes to cancer

  This work looks at autoantibodies in people with scleroderma to find antibody patterns that signal higher or lower risk of cancer near disease onset.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11197594

• How skin cells and their signals change in systemic sclerosis and localized scleroderma

  This project looks at how skin cells and immune cells behave differently in people with systemic sclerosis and localized scleroderma to find biological targets for better treatments.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11193262

• CD38 and NAD metabolism in scleroderma

  This research looks at whether changing the activity of CD38 and related NAD metabolism can reduce the scarring that damages organs in people with systemic sclerosis (scleroderma).

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11187263

• Understanding Scleroderma in Twins and the Role of Estrogen

  This research looks at how genes and environment affect scleroderma in twins and explores the role of estrogen in African American patients with a severe form of the disease.

  NIH research Medical University of South Carolina · Charleston, United States · NIH-11129920

• Understanding how T cells affect skin cells in scleroderma

  This study is looking at how certain immune cells called T cells affect the worsening of scleroderma, a condition that causes hardening of the skin and organs, to help find new ways to treat its symptoms.

  NIH research Benaroya Research Inst at Virginia Mason · Seattle, United States · NIH-11114053

• Investigating lymphatic signaling in scleroderma fibrosis

  This study is looking at how certain signals in the lymphatic system might affect people with scleroderma, with the goal of finding new ways to improve treatments for this condition.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11112303

• Using esomeprazole to treat scleroderma

  This study is exploring whether esomeprazole, a medicine usually for heartburn, can help people with scleroderma by reducing lung inflammation and fibrosis, and you might have a chance to join the trials to see if it works!

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11091993

• Using imaging technology to measure skin changes in scleroderma

  This study is testing a new way to take pictures of the skin to help people with scleroderma see how their skin is changing over time, making it easier for doctors to track their condition and how well treatments are working.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11048278

• Understanding how the COVID-19 vaccine works in patients with lupus and scleroderma

  This study is looking at how well the COVID-19 vaccine works for people with lupus and scleroderma, two autoimmune diseases, to see how their immune systems respond and to ensure the vaccine is safe for them.

  NIH research Stanford University · Stanford, United States · NIH-11047679

• Using patient data to predict health events in scleroderma

  This study is looking at how scleroderma affects people in different ways over time, so we can find patterns that help doctors give better, personalized care to patients.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11042211

• Investigating how the Hippo pathway affects scleroderma development

  This study is looking at how a specific cell signaling pathway might be involved in scleroderma, a condition that thickens the skin and can impact other organs, to help find new ways to treat it.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11013342

• New treatment for lung fibrosis related to scleroderma

  This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.

  NIH research Thendor Therapeutics LLC · Lexington, United States · NIH-11006098

• Using advanced MRI to assess blood flow and tissue health in scleroderma patients

  This study is looking at how special MRI scans can help us understand blood flow and tissue health in people with scleroderma, so we can find better ways to manage the complications that affect their daily lives.

  NIH research Yale University · New Haven, United States · NIH-10984568

• Understanding how autoantibodies in scleroderma relate to cancer risk

  This study is looking at how certain immune markers in people with scleroderma might help us understand their risk of developing cancer, so we can better support patients based on their unique profiles.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10981317

• Investigating skin cell changes in systemic sclerosis and localized scleroderma

  This study is looking at how certain skin cells change in people with systemic sclerosis and localized scleroderma, which cause painful skin thickening, to find out what drives these changes and how we might improve treatments for those affected.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-10929336

• Investigating how specific immune cells relate cancer and scleroderma.

  This study is looking at how having scleroderma might be linked to cancer by exploring how the immune system can sometimes mistakenly attack healthy tissues while fighting cancer, especially in patients who have certain antibodies; it's for people with scleroderma who are concerned about their cancer risk.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10927344

• Developing a treatment to inhibit STAT3 for lung scleroderma

  This study is looking at a new treatment that could help people with lung scleroderma by targeting a protein called STAT3, which may help reduce lung inflammation and improve breathing and overall well-being.

  NIH research Altay Therapeutics, INC. · San Carlos, UNITED STATES · NIH-10922280

• Understanding how CD38 affects NAD metabolism in scleroderma

  This study is looking at how a protein called CD38 affects a substance in the body that helps with energy and may play a role in the development of scleroderma, a condition that causes hardening and damage to organs, and it aims to find new treatment options by working with patient samples and animal models.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-10913581

• Investigating the role of a specific protein in lung fibrosis related to scleroderma

  This study is looking at how a protein called BHLHB2 affects lung scarring in people with scleroderma, hoping to find new ways to help treat lung problems caused by this condition.

  NIH research Medical University of South Carolina · Charleston, United States · NIH-10899503

• Investigating the role of a specific enzyme in lung disease related to scleroderma

  This study is looking at how a specific enzyme might play a role in worsening pulmonary arterial hypertension (PAH) in people with scleroderma, with the goal of finding new ways to improve treatment for those affected.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10888299

• Understanding how T cells contribute to skin fibrosis in scleroderma

  This study is looking at how certain immune cells called CD4+ T cells contribute to skin thickening in scleroderma, with the hope of finding new ways to understand and treat the condition better for patients.

  NIH research Yale University · New Haven, United States · NIH-10789718

• Creating a new oral medication to treat systemic scleroderma

  This study is testing a new oral medication designed to help people with systemic scleroderma by targeting the damage caused by the disease, with the hope of improving their health and quality of life.

  NIH research Apie Therapeutics, INC. · Cary, United States · NIH-10609109

Related topics

Quick answers

How many Scleroderma clinical trials are recruiting right now?

20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in United States (9 trials), France (5 trials), Turkey (Türkiye) (3 trials), China (3 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 2/3: 2, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →